3rd Annual Guggenheim Healthcare Innovation Conference
Logotype for Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals (SNDX) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Syndax Pharmaceuticals Inc

3rd Annual Guggenheim Healthcare Innovation Conference summary

11 Nov, 2026

Commercial performance

  • Latest-quarter revenue was $61 million for Revuforj; revenue growth was 11% for Revuforj and 12% for Niktimvo.

  • Revuforj leads new patient starts across the category; 80%+ of relapsed/refractory category revenue remains in that setting.

  • Revuforj growth is supported by new starts, recurring revenue, longer treatment, transplant and post-transplant maintenance.

  • Niktimvo had more than 300 new patient starts and penetration above one-third in the third-line-plus market; fourth-line penetration is higher.

Revuforj expansion and clinical evidence

  • For KMT2A, about 50% of patients reached transplant and about 60% of those returned for maintenance; management sees potential to reach 60% and 70%–80%, respectively.

  • For NPM1, about 40% reached transplant and 50% of those returned for maintenance this quarter; management sees potential for 60%–70% to return for maintenance.

  • Treatment duration is about seven months for responding patients not transplanted and over nine months for patients on maintenance; physicians anticipate 1–2 years of maintenance, potentially longer.

  • EVOLVE and REVEAL frontline trials have hundreds of sites open; ASH updates will include phase I/II data, with further trial progress expected to be discussed in 2027.

  • ASH has 14 accepted abstracts, including seven oral presentations; BEAT AML VEN-AZA combination data show a 68% CR rate and 24-month median OS overall, while NPM1 median OS is not reached and 56% are alive at two years.

ASH research and treatment trends

  • AUGMENT data show 40% of patients proceeding to transplant lacked CR/CRh, including other morphological remissions; a phase I maintenance study will report tolerability, feasibility and MRD clearance through one to two years.

  • Nearly half of Revuforj use is off-label, primarily combinations with VEN-AZA, reflecting earlier treatment and physician interest in combination regimens.

  • The INTERCEPT study evaluates treatment at MRD recurrence; ASH data will include high rates of MRD eradication and MRD responses.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Syndax Pharmaceuticals